C3.ai, Inc.

Case Overview
43 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 10/21/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: C3.ai, Inc. |
Court: | Court: Northern District of California |
Case Number: | Case Number: 3:25cv07129 |
Class Period: | Class Period: 02/26/2025 - 08/08/2025 |
Ticker: | Ticker: AI |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of those who acquired C3.ai, Inc. (“C3.ai” or the “Company”) (NYSE:AI) securities during the period of February 26, 2025 through August 8, 2025, inclusive (“the Class Period”). Investors have until October 21, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On August 8, 2025, C3 AI announced disappointing preliminary financial results for the first quarter of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026. The Company attributed its poor sales results and lowered guidance on “the reorganization with new leadership” and the health ailments of its Chief Executive Officer. Following this news, the price of C3 AI’s common stock declined dramatically. From a closing market price of $22.13 per share on August 8, 2025, C3 AIs stock price fell to $16.47 per share on August 11, 2025, a decline of about 25.58% in the span of just a single day.
The lawsuit alleges that defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of C3 AI’s growth; notably, that its Chief Executive Officer health was having a significant impact on the Company’s ability to close deals, that its management was unable or otherwise ineffectual in minimizing that impact, and that C3 AI would not be able to execute upon its profit and growth potential as a result.
On August 8, 2025, C3 AI announced disappointing preliminary financial results for the first quarter of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026. The Company attributed its poor sales results and lowered guidance on “the reorganization with new leadership” and the health ailments of its Chief Executive Officer. Following this news, the price of C3 AI’s common stock declined dramatically. From a closing market price of $22.13 per share on August 8, 2025, C3 AIs stock price fell to $16.47 per share on August 11, 2025, a decline of about 25.58% in the span of just a single day.
The lawsuit alleges that defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of C3 AI’s growth; notably, that its Chief Executive Officer health was having a significant impact on the Company’s ability to close deals, that its management was unable or otherwise ineffectual in minimizing that impact, and that C3 AI would not be able to execute upon its profit and growth potential as a result.